This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Altomare, G.F. Articles by Polenghi, M.M. Search for Related Content PubMed PubMed Citation Articles by Altomare, G.F. Articles by Polenghi, M.M. Social Bookmarking                         What's this?

Ketanserin in the Treatment of Progressive Systemic Sclerosis

From the 2nd Department of Dermatology, University of Milan, Milan, Italy

P.D. Pigatto

From the 2nd Department of Dermatology, University of Milan, Milan, Italy

M.M. Polenghi

From the 2nd Department of Dermatology, University of Milan, Milan, Italy

Now progressive systemic sclerosis (PSS) is considered a disease of small vessels with which many immunologic alterations are associated. The presence in the blood of large amounts of serotonin can be considered a very important aggravating factor able to cause the sclerodermic alterations.

The authors have treated 10 PSS patients with ketanserin, a selective antagonist of the S₂ serotonin receptors, which are found in small vessels and platelets.

Their results show that ketanserin represents an efficacious and very well tolerated therapy for treatment of the initial vascular symptoms of PSS.

Angiology, Vol. 39, No. 7, 583-586 (1988)
DOI: 10.1177/000331978803900705


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?